Arrowhead Pharmaceuticals, Inc. (ARWR) Stock Analysis
Range Bound setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $73.15: Quality below floor (3.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.0/10. Specifically: High short interest: 13%; Elevated put/call ratio: 1.90; Below-average business quality.
Arrowhead Pharmaceuticals is an RNAi therapeutics company with 18 clinical-stage candidates and one approved product, REDEMPLO (plozasiran) for Familial Chylomicronemia Syndrome, commercially launched in 2025. Revenue comes from milestone and royalty payments under collaboration... Read more
Sell if holding. Engine safety override at $73.15: Quality below floor (3.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.0/10. Specifically: High short interest: 13%; Elevated put/call ratio: 1.90; Below-average business quality. Chart setup: RSI 56 mid-range, Bollinger mid-band. Score 4.0/10, high confidence.
Passes 6/8 gates (clean insider activity, no SEC red flags, news boost analyst 0.40, earnings proximity 80d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio. Suitability: moderate.
Recent Developments — Arrowhead Pharmaceuticals, Inc.
Latest news
- Arrowhead (ARWR) Stock Outlook | Q1 2026: Profit Disappoints - PEG Ratio - Newser — Newser negative
- Arrowhead (ARWR) Stock Outlook | Q1 2026: Profit Disappoints - Event Driven - Newser — Newser neutral
- Why Arrowhead Pharmaceuticals (ARWR) Is Up 6.8% After Australia Approves First-In-Class FCS Therapy REDEMPLO - simplywal — simplywall.st positive
- JPMorgan Expects Arrowhead Pharma Stock to Rally on RNAi Portfolio Growth - TIKR.com — TIKR.com positive
- ARWR rallies 7% this week as Europe edges closer to Redemplo approval amid analyst optimism - MSN — MSN positive
Generated 2026-05-20T20:21:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
5 floor-breakers
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Volatile — 5.6% daily ATR makes tight stops impractical. Position-size conservatively.static
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
Unprofitable operations — net margin -48.4%. Quality floor flags this regardless of sector context.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $73.15: Quality below floor (3.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.0/10. Specifically: High short interest: 13%; Elevated put/call ratio: 1.90; Below-average business quality. Chart setup: RSI 56 mid-range, Bollinger mid-band. Prior stop was $68.77. Score 4.0/10, high confidence.
Take-profit target: $76.71 (+3.7% upside). Prior stop was $68.77. Stop-loss: $68.77.
Quality below floor (3.0 < 4.0).
Arrowhead Pharmaceuticals, Inc. trades at a P/E of N/A (forward -17.7). TrendMatrix value score: 3.0/10. Verdict: Sell.
19 analysts cover ARWR with a consensus score of 4.1/5. Average price target: $88.
What does Arrowhead Pharmaceuticals, Inc. do?Arrowhead Pharmaceuticals is an RNAi therapeutics company with 18 clinical-stage candidates and one approved product,...
Arrowhead Pharmaceuticals is an RNAi therapeutics company with 18 clinical-stage candidates and one approved product, REDEMPLO (plozasiran) for Familial Chylomicronemia Syndrome, commercially launched in 2025. Revenue comes from milestone and royalty payments under collaboration agreements with Sarepta, Amgen, Takeda, GSK, and Novartis, plus initial REDEMPLO product sales.